Treatment of Cellulitis in Diabetic Foot
Infection Severity Classification
- The Infectious Diseases Society of America recommends classifying diabetic foot infections as mild, moderate, or severe, based on criteria such as the extent of cellulitis, presence of systemic illness, and involvement of deeper tissues 1
- Mild infection is characterized by cellulitis extending <2 cm around the ulcer, limited to skin or superficial subcutaneous tissues, with no systemic illness 1
- Moderate infection is characterized by cellulitis extending >2 cm, with lymphangitic streaking, deep-tissue abscess, or involvement of muscle/tendon/joint/bone, but the patient is systemically well 1
- Severe infection is characterized by systemic toxicity, such as fever, chills, tachycardia, hypotension, confusion, leukocytosis, acidosis, severe hyperglycemia, or azotemia 1
Empirical Antibiotic Selection by Severity
- The American College of Clinical Pharmacy recommends empirical antibiotic therapy targeting gram-positive cocci, such as S. aureus, with narrow-spectrum agents like clindamycin for mild infections 2
- For moderate-to-severe infections, the American College of Clinical Pharmacy recommends broad-spectrum coverage with piperacillin-tazobactam or fluoroquinolone plus clindamycin 2
Critical Adjunctive Measures
- The American Diabetes Association recommends optimizing glycemic control as a critical adjunctive measure in the treatment of diabetic foot infections 2
- The Society for Vascular Surgery recommends assessing for critical limb ischemia and considering early revascularization for patients with severe ischemia 3
Definitive Therapy and Monitoring
- The Infectious Diseases Society of America recommends obtaining deep tissue cultures via biopsy or curettage after debridement to guide antibiotic therapy 3
- The American College of Clinical Pharmacy recommends adjusting antibiotics based on culture results, focusing on virulent species such as S. aureus and group A/B streptococci 3
Special Pathogen Considerations
- The American College of Clinical Pharmacy recommends considering anti-pseudomonal therapy for patients with macerated wounds, residence in warm climates, or previous Pseudomonas isolation from the affected site 3
- The Infectious Diseases Society of America recommends considering anaerobic coverage for patients with necrotic or gangrenous infections, chronic wounds, or foul-smelling discharge 2